Cytonus Therapeutics to Present CA-IL12 Breast Cancer Data at the 2019 BIO International Convention

SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics Inc., a biotechnology company developing new
platforms for delivering biologics, announced today that it will be
presenting preclinical data for its Cargocyte™ technology platform
program targeting difficult to treat Breast Cancer at the BIO
International Convention meeting June 3-6 in Philadelphia, PA.

Cargocytes are engineered allogenic cell lines that can carry a variety
of payloads like small molecule compounds, gene editing therapies,
therapeutic RNAs, and powerful biologics such as immune modulating
cytokines, antibodies and oncolytic viruses.

“We are honored to have been selected to present Cytonus’
first-of-its-kind Cargocyte™ technology platform at this year’s BIO
convention and look forward to sharing our promising CA-IL12 data in
treating Triple Negative Breast Cancer in preclinical animal models,”
said Remo Moomiaie-Qajar, M.D., president and CEO of Cytonus.

Details of the presentation:

Cytonus Therapeutics, Inc.

Cytonus Therapeutics Inc. is a biopharmaceutical company developing a
next-generation Adoptive Cellular Transport platform called Cargocytes™.
The San Diego-based company’s proprietary Cargocyte™ platform consists
of cellular-engineered transporters of a multiplicity of therapeutic
payloads to tissue in a selective, controllable and potent off-the-shelf
cellular therapy for the potential treatment of several disease across
multiple therapeutic areas. Cytonus’ initial focus is to advance
Cargocyte™ candidates for the treatment of rare and difficult to treat
cancers and inflammatory diseases. For more information, visit www.cytonus.com
or follow us on LinkedIn.

Statements in this news release, which relate to other than strictly
historical facts, such as statements about Cytonus’ plans and
strategies, new and existing products and technologies, anticipated
clinical and regulatory pathways, and markets for its products are
forward-looking statements. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify forward-looking
statements that speak only as of the date hereof. Such statements
involve risks and uncertainties that could cause actual results to
differ materially from anticipated results due to many factors,
including regulatory and development risks. Cytonus undertakes no
obligation to publicly update or revise any forward-looking statements.
This news release is neither an offer to sell, nor the solicitation of
any offer to purchase, any security.

Contacts

Henry Gillespie
[email protected]
614-623-9673